Protagonist Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 4 days.
- Recent price momentum is +12.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 15.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 25.7x | Better than 29% |
| Forward P/E | 45.9x | Better than 8% |
| Price / Sales | 15.5x | Better than 7% |
| P/E vs own 5-yr range | 78th pctl | Better than 28% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D-
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -343.6% | Better than 4% |
| Net margin | -282.8% | Better than 4% |
| Return on equity | -20.2% | Better than 16% |
| Return on invested capital | -23.1% | Better than 12% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -21.3% | Better than 29% |
| 6-month return | 22.4% | Better than 85% |
| 12-month return (ex latest month) | 62.1% | Better than 88% |
| Distance below 52-week high | 24.5% | Better than 51% |
Financial Health B-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 12.7x | Better than 95% |
| Debt to assets | 1.5% | Better than 90% |
| Interest coverage | -107.4x | Better than 5% |
| Free cash flow / net income | 66.4% | Better than 20% |
Analyst View A-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 48.3% | Better than 65% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 124.02
- Open
- 123.41
- Day range
- 120.15 - 125.91
- Avg price
- 122.73
- Volume
- 600.73K
- Turnover
- 73.73M
- Turnover ratei
- 1.13%
- Volume ratioi
- 1.04
- Amplitudei
- 4.65%
- 52-week rangei
- 77.00 - 160.81
Valuation
- P/Ei
- -59.22
- P/E (TTM)i
- 25.67
- P/Bi
- 7.30
- EPSi
- -2.05
- Book value / shi
- 16.62
- Net profit
- -133.80M
- Net assets
- 1.08B
Share structure
- Market cap
- 7.92B
- Float capi
- 6.48B
- Shares out
- 65.27M
- Float sharesi
- 53.36M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2016-08-11
24.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-3.23M net over the window
Short interest
- Shares short
- 10.24M
- % of floati
- 15.83%
- Days to coveri
- 16.89
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Protagonist Therapeutics (PTGX)?
Protagonist Therapeutics last traded at 121.40. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Protagonist Therapeutics's market cap?
About 7.92B.
What is the P/E ratio of Protagonist Therapeutics?
The trailing twelve-month P/E is 25.67, above its own 5-year average of 16.61 — toward the top of its historical range (78.31% percentile). See the Valuation tab for the full history.
Does Protagonist Therapeutics pay a dividend?
Protagonist Therapeutics does not currently pay a regular dividend.
Is Protagonist Therapeutics a buy according to analysts?
The consensus of 13 analysts is a Buy rating, with an average 12-month price target of 180.00, which implies 48.3% upside from the current price. This is not investment advice.
What is Protagonist Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Protagonist Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Protagonist Therapeutics discussion 0 comments